<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03060629</url>
  </required_header>
  <id_info>
    <org_study_id>CR108263</org_study_id>
    <secondary_id>VAC89220HPX2008</secondary_id>
    <secondary_id>HVTN 705</secondary_id>
    <secondary_id>HVTN 705/VAC89220HPX2008</secondary_id>
    <nct_id>NCT03060629</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Efficacy Study of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-adjuvanted Clade C gp140 in Preventing HIV-1 Infection in Adult Women in Sub-Saharan Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Vaccines &amp; Prevention B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Vaccines &amp; Prevention B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the preventive vaccine efficacy (VE), safety&#xD;
      and tolerability of a heterologous prime/boost regimen utilizing Ad26.Mos4.HIV and&#xD;
      aluminum-phosphate adjuvanted Clade C gp 140 for the prevention of Human Immuno Virus (HIV)&#xD;
      infection in HIV-seronegative women residing in sub-Saharan Africa from confirmed HIV-1&#xD;
      infections diagnosed between the Month 7 and Month 24 visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 3, 2017</start_date>
  <completion_date type="Anticipated">July 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 23, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Sponsor will be also blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine Efficacy (VE) as Derived From Confirmed HIV-1 Infections Diagnosed Between the Month 7 and Month 24 Visits</measure>
    <time_frame>From Month 7 to Month 24</time_frame>
    <description>VE (7-24) is defined as the cumulative incidence ratio (vaccine/placebo) of the HIV-1 endpoint between Month 7 and Month 24 after enrollment in the Per-Protocol (PP) population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Reactogenicity Sign or Symptom</measure>
    <time_frame>3 days after each vaccination</time_frame>
    <description>Each participant's reactogenicity will be counted once under the maximum severity for each injection visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>30 Days after each vaccination (Approximately up to 42 Months)</time_frame>
    <description>Adverse events by body system, severity, and assessed relationship to study products.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaccine Efficacy as Derived From Confirmed HIV1 Infections Diagnosed Between Enrollment and the Month 24 Visit</measure>
    <time_frame>From Baseline to 24 Months</time_frame>
    <description>VE (0-24) is defined as the cumulative incidence ratio (vaccine/placebo) of the HIV-1 endpoint between Month 0 and Month 24 after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Efficacy as Derived From Confirmed HIV1 Infections Diagnosed Between Enrollment and the end of Study Visit</measure>
    <time_frame>Baseline up to Month 57 (End of study)</time_frame>
    <description>VE (0-57) is defined as the cumulative incidence ratio (vaccine/placebo) of the HIV-1 endpoint between Month 0 and Month 57 (end of study) after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Efficacy as Derived From Confirmed HIV1 Infections Diagnosed Between the Month 12 and the Month 24 Visits</measure>
    <time_frame>From Month 12 to Month 24</time_frame>
    <description>VE (12-24) is defined as the cumulative incidence ratio (vaccine/placebo) of the HIV-1 endpoint between Month 12 and Month 24 after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Efficacy as Derived From Confirmed HIV1 Infections Diagnosed Between the Month 12 and end of Study Visit</measure>
    <time_frame>From Month 12 to Month 57 (End of study)</time_frame>
    <description>VE (12-57) is defined as the cumulative incidence ratio (vaccine/placebo) of the HIV-1 endpoint between Month 12 and Month 57 (end of study) after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of the Vaccine Regimen</measure>
    <time_frame>Up to Month 24</time_frame>
    <description>Immunogenicity of the vaccine regimen, assessed by Vaccine-specific antibody and T cell responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity and Immune Response Biomarkers as Correlates of Risk of Subsequent HIV Acquisition</measure>
    <time_frame>Up to Month 24</time_frame>
    <description>Immunogenicity and Immune Response are assessed by BiomarkersVaccine-specific antibody and T cell responses correlated with vaccine efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Efficacy Assessed by Various Baseline and Demographic Characteristics</measure>
    <time_frame>Up to Month 24</time_frame>
    <description>The vaccine efficacy assessed by various baseline and demographic characteristics diagnosed by HIV-1 infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotypic Characteristics of Viral Sequences From HIV-1 Infected Participants at HIV-1 Diagnosis, Such as Signature Site Mutations</measure>
    <time_frame>From Month 12 to Month 24</time_frame>
    <description>The genotypic characteristics of viral sequences from HIV-1-infected participants at HIV-1 diagnosis assessed by signature site mutations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Genomic Sequences of Viral Isolates From HIV-1 Infected Vaccine and Placebo Recipients and Assessment by Sieve Analysis Methods of Whether There is Evidence of Vaccine-Induced Immune Pressure on the Viral Sequences</measure>
    <time_frame>Baseline up to Month 57</time_frame>
    <description>Viral sequences from HIV-1-infected participants at HIV-1 diagnosis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2637</enrollment>
  <condition>HIV-1</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Ad26.Mos4.HIV 5*10^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) injection into the left deltoid on Months 0, 3, 6, and 12 and Clade C gp140 (250 [microgram] mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive Placebo for Ad26.Mos4.HIV as 0.5 mL into the left deltoid on Months 0, 3, 6, and 12 and Placebo for Clade C gp140 / Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.Mos4.HIV</intervention_name>
    <description>Participants will receive Ad26.Mos4.HIV 5x10^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) into the left deltoid on Months 0, 3, 6, and 12.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Clade C gp140</intervention_name>
    <description>Participants will receive Clade C gp140 (250 mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive matching placebo.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sexually active, defined as having had sexual intercourse with a male partner at least&#xD;
             twice in the past 30 days prior to screening, and is considered by the site staff to&#xD;
             be at risk for Human Immunodeficiency Virus (HIV) infection&#xD;
&#xD;
          -  Access to a participating HIV Vaccine Trials Network (HVTN) Clinical Research Sites&#xD;
             (CRS) and willingness to be followed for the planned duration of the study&#xD;
&#xD;
          -  Willingness to discuss HIV infection risks and willing to receive HIV risk reduction&#xD;
             counseling and appropriate referrals to minimize HIV acquisition, as applicable&#xD;
&#xD;
          -  Negative beta human chorionic gonadotropin (beta-HCG) pregnancy test performed prior&#xD;
             to vaccination on the day of initial vaccination. Persons who are NOT of reproductive&#xD;
             potential due to having undergone total hysterectomy or bilateral oophorectomy&#xD;
             (verified by medical records), are not required to undergo pregnancy testing&#xD;
&#xD;
          -  Participants must also agree not to seek pregnancy through alternative methods, such&#xD;
             as artificial insemination or in vitro fertilization until 3 months after the last&#xD;
             vaccination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Investigational research agents received within 30 days before first vaccination&#xD;
&#xD;
          -  HIV vaccine(s) received in a prior HIV vaccine trial. For volunteers who have received&#xD;
             control/placebo in an HIV vaccine trial, the HVTN 705/HPX2008 (Protocol Safety Review&#xD;
             Team) PSRT will determine eligibility on a case-by-case basis&#xD;
&#xD;
          -  Live attenuated vaccines received within 30 days before first vaccination or scheduled&#xD;
             within 14 days after injection (example: measles, mumps, and rubella [MMR]; oral polio&#xD;
             vaccine [OPV]; varicella; yellow fever)&#xD;
&#xD;
          -  Any vaccines that are not live attenuated vaccines and were received within 14 days&#xD;
             prior to first vaccination (example, tetanus, pneumococcal, Hepatitis A or B)&#xD;
&#xD;
          -  Immunosuppressive medications received within 6 months before first vaccination&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Vaccines &amp; Prevention B.V. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Vaccines &amp; Prevention B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC Lilongwe Project</name>
      <address>
        <city>Lilongwe</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polana Cani√ßo Health Research and Training Center (CISPOC)</name>
      <address>
        <city>Maputo</city>
        <country>Mozambique</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josha Research</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masiphumelele Research Centre</name>
      <address>
        <city>Cape Town</city>
        <zip>7975</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ndlovu Elandsdoorn Site</name>
      <address>
        <city>Dennilton</city>
        <zip>0485</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Diepkloof</city>
        <zip>1862</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute Klerksdorp Clinical Research Centre</name>
      <address>
        <city>Klerksdorp</city>
        <zip>2571</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qhakaza Mbokodo Research Centre</name>
      <address>
        <city>KwaZulu-Natal</city>
        <zip>4030</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South African Medical Research Council Chatsworth Clinical Research Site</name>
      <address>
        <city>KwaZulu-Natal</city>
        <zip>4030</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for the AIDS Programme of Research in South Africa</name>
      <address>
        <city>KwaZulu-Natal</city>
        <zip>4110</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South African Medical Research Council Tongaat Clinical Research Site</name>
      <address>
        <city>KwaZulu-Natal</city>
        <zip>4399</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanza Clinical Research Centre : Mamelodi</name>
      <address>
        <city>Mamelodi East</city>
        <zip>122</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nelson Mandela Academic Clinical Research Unit 'NeMACRU'</name>
      <address>
        <city>Mthatha</city>
        <zip>5099</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MeCRU Clinical Research Unit</name>
      <address>
        <city>Pretoria</city>
        <zip>204</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute Rustenburg Clinical Research Site</name>
      <address>
        <city>Rustenburg</city>
        <zip>300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Centre</name>
      <address>
        <city>Soshanguve</city>
        <zip>152</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perinatal HIV Research Unit (PHRU), Kliptown</name>
      <address>
        <city>Soweto</city>
        <zip>1809</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Aurum Institute: Tembisa - Clinic 4</name>
      <address>
        <city>Tembisa</city>
        <zip>1632</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Infectious Disease Research in Zambia (CIDRZ)</name>
      <address>
        <city>Lusaka</city>
        <zip>10101</zip>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Family Health Research in Zambia (CFHRZ)</name>
      <address>
        <city>Lusaka</city>
        <zip>P/BagE891</zip>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Family Health Research in Zambia (CFHRZ)</name>
      <address>
        <city>Ndola</city>
        <zip>240262</zip>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary's Clinic</name>
      <address>
        <city>Chitungwiza</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Zimbabwe-UCSF</name>
      <address>
        <city>Harare - Seke South</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malawi</country>
    <country>Mozambique</country>
    <country>South Africa</country>
    <country>Zambia</country>
    <country>Zimbabwe</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 17, 2017</study_first_submitted>
  <study_first_submitted_qc>February 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

